Summary
Prostate-Specific Antigen (PSA) is a widely used serum marker to aid in the diagnosis of prostate cancer and monitor its treatment. PSA by itself has limited specificity, and cannot distinguish between early stage prostate cancer and benign prostatic hyperplasia (BPH), resulting in many unnecessary biopsies. The specificity of PSA for prostate cancer was improved when it was discovered that complex and free forms of PSA existed in serum and the ratio of free to complexed PSA (%free PSA) correlated to prostate cancer. It is now known that the free form of PSA is actually composed of several proenzyme forms and enzymatically nicked PSA. The major nicked form is common to benign hyperplasia and is referred to as Benign PSA (BPSA). The proenzyme forms of PSA are collectively called proPSA and are associated with prostate cancer. There are three recognized proPSA isoforms ([−5/−7]proPSA, [−4]proPSA, and [−2]proPSA) that increase the utility of PSA in prostate cancer diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mikolajczyk, S.D. and Rittenhouse, H.G. (2003) Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer Keio J Med 52, 86–91.
Mikolajczyk, S.D., Marker, K.M., Millar, L.S., Kumar, A., Saedi, M.S., Payne, J.K., Evans, C.L., Gasior, C.L., Linton, H.J., Carpenter, P., and Rittenhouse, H.G. (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer Cancer Res 61, 6958–6963.
Mikolajczyk, S.D., Marks, L.S., Partin, A.W., and Rittenhouse, H.G. (2002) Free Prostate-specific Antigen in serum is becoming more complex Urology 50, 797–802.
Mikolajczyk, S.D., Song,Y., Wong, J.R., Matson, R.S., and Rittenhouse, H.G. (2004) Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 37, 519–528.
Balk, S.P. Ko, Y-J., and Bubley, G.J. (2003) Biology of Prostate-specific Antigen J Clin Oncol 21, 383–391.
Haese, A., Graefen, M., Huland, H., and Lilja, H. (2004) Prostate-specific Antigen and related isoforms in the diagnosis and management of prostate cancer Curr Urol Reports 5, 231–240.
Kumar, A., Mikolajczyk, S.D., Goel, AS, Millar, L.S., and Saedi, M.S. (1997) Expression of pro forms of Prostate-specific Antigen by mammalian cells and its conversion to mature, active form by Human Kallikrein2 Cancer Res 57, 3111–3114.
Peter, J., Unverzagt, C., Krogh, T.N., Vorm, O., and Hoesel, W. (2001) Identification of precursor forms of free Prostate-specific Antigen in serum of prostate cancer patients by immunosorption and mass spectrometry Cancer Res 61, 957–962.
Chan, T.Y., Mikolajczyk, S.D., Lecksell, K., Shue, M.J., Rittenhouse, H.G., Partin, A.W., and Epstein, J.I. (2003) Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of Prostate-specific Antigen Urology 62, 177–181.
Mikolajczyk, S.D., Catalona, W.J., Evans, C.L. Linton, H.J., Millar, L.S. Marker, K.M, Katir, D., Amirkhan, A., and Rittenhouse, H.G. (2004) Proenzyme forms of Prostate-specific Antigen in serum improve the detection of prostate cancer Clin Chem 50, 1017–1025.
Naya, Y., Fritsche, H.A., Bhadkamkar, V.A., Mikolajczyk, S.D., Rittenhouse, H.G., and Babaian, R.J. (2005) Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer Urol Oncol 23, 16–21
Sokoll, L.J., Chan, D.W., Mikolajczyk, S.D., Rittenhouse, H.G., Evans, C.L., Linton, H.J., Mangold, L.A., Mohr, P., Bartsch, G., Klocker, H., Horninger, W., and Partin, A. (2003) Proenzyme PSA for the early detection of prostate cancer in the 2.5–4.0 ng/mL total PSA range: Primary analysis Urology 61, 274–276.
Catalona, W.J., Bartsch, G., Rittenhouse, H.G., Evans, C.L., Linton, H.J., Amirkhan, A., Horninger, W., Klocker, H., and Mikolajczyk, S.D. (2003) Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/mL J Urol 170, 2181–2185.
Catalona, W.J., Bartsch, G., Rittenhouse, H.G., Evans, C.L., Linton, H.J., Horninger, W., Klocker, H., and Mikolajczyk, S.D. (2004) Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate specific antigen J Urol 171, 2239–2244.
Weinzierl, C.F, Su, S.X., Pierson, T.B., Arockiasamy, D.A., Mizrahi, I.A., Broyles, D. L, and Tam, J.E., (2007) (C-38) Measuring [−2]proPSA in serum: Analytical performance of the Access p2PSA assay from Beckman Coulter. Annual Meeting of the American Association for Clinical Chemistry. Abstract No. C-38.
Sokoll, L.J., Wang, Y., Feng, Z., Kagan, J., Partin, A.W., Sanda, M.G., Thompson, I.M., and Chan, D.W., (2008) [-2]proPSA for prostate cancer detection: an NCI Early Detection Research Network validation study J Urol 180, 539–543.
Stephan, C., Cammann, H., Jung, K., and Lein, M. (2008) –2proPSA enhanced prostate cancer detection at tPSA 2–10 \(\upmu\)g/l within multivariate models and detects aggressive Pca The 2nd World Congress on Controversies in Urology, Abstract No. 457762.
Lein, M., Semjonow, A., Graefen, M., Kwiatkowski, M., Abramjuk, C., Stephan, C. et al. (2005) A multicenter clinical trial on the use of (−5, −7) pro prostate specific antigen J Urol 174, 2150–2153.
Stephan, C., Meyer, H.A., Kwiatkowski, M., Recker, F. Camman, H. Loening, S. A. et al. (2006) A (−5, −7) proPSA based artificial neural network to detect prostate cancer Eur Urol 50, 1014–1020.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Tam, J.E. (2009). PSA Isoforms: [−2]proPSA Significant Adjunct to Free PSA. In: Ankerst, D.P., Tangen, C.M., Thompson, I.M. (eds) Prostate Cancer Screening. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-281-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-60327-281-0_15
Publisher Name: Humana Press
Print ISBN: 978-1-60327-280-3
Online ISBN: 978-1-60327-281-0
eBook Packages: MedicineMedicine (R0)